Pfizer Inc. recently announced that it has made an agreement with GlaxoSmithKline to acquire Nimenrix and Mencevax vaccines for meningitis A, C, W135 and Y.
The total cost of the acquisition amounts to $130 million and will supplement these two complementary, high-quality vaccines into Pfizer’s portfolio. This move enables Pfizer to extend worldwide reach.
Nimenrix is designed to prevent meningococcal serogroups A, C, W-135 and Y. It is a conjugate, single-dose, tetanus toxoid vaccine that may protect people from Neisseria meningitides, which is a rare but extremely contagious disease that causes both disability and death.
Mencevax is an unconjugated, single-dose, meningococcal polysaccharide vaccine that is designed to protect against meningococcal polysaccharide serogroups A, C, W-135 and Y.
“The addition of Nimenrix and Mencevax is an important milestone for Pfizer Vaccines,” Pfizer Vaccines President Susan Silbermann said. “Adding these two innovative and complementary vaccines to our current portfolio will allow us to more completely respond to meningococcal disease outbreaks as well as proactively address a critical public health need – the prevention of meningococcal disease across all ages. Acquiring these quadrivalent vaccines will broaden our ability to address the burden of meningococcal meningitis – an uncommon but serious and sometimes fatal disease. This helps us to further fulfill our vision to protect lives with innovative vaccines to fight serious diseases worldwide and gives us even greater capability to meet the needs of the global community we serve.”